title: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo.
abstract: Previous studies have suggested that osteopontin, an arginine-glycine-aspartate-containing secreted protein, might be important in macrophage accumulation during interstitial nephritis and wound healing. The current study investigated the role of osteopontin in intradermal macrophage infiltration using immunohistochemistry and neutralizing antibodies. Purified osteopontin induced macrophage accumulation after injection in rat dermis and facilitated adhesion and migration of cultured macrophage-like cells in vitro. Intradermal injection of N-formyl-met-leu-phe (FMLP), a potent macrophage chemotactic peptide, induced a macrophage-rich infiltrate at the site of injection. Most of these macrophages expressed high levels of osteopontin as shown by immunochemical analysis. To determine whether osteopontin expressed by macrophages was required for their infiltration, we treated rats with either anti-osteopontin neutralizing antibody (OP199) or nonimmune antibody. We found that FMLP-induced macrophage accumulation was largely inhibited (>60%) by anti-osteopontin antibody treatment compared with rats receiving nonimmune antibody. These data support the hypothesis that osteopontin may be a critical mediator of inflammation in specific disease and injury states, potentially by promoting macrophage adhesion and migration.
authors.affiliation: Department of Pathology, University of Washington, Seattle 98195, USA. ceci@u.washington.edu
authors.forename: C M
authors.initials: CM
authors.lastname: Giachelli
authors.forename: D
authors.initials: D
authors.lastname: Lombardi
authors.forename: R J
authors.initials: RJ
authors.lastname: Johnson
authors.forename: C E
authors.initials: CE
authors.lastname: Murry
authors.forename: M
authors.initials: M
authors.lastname: Almeida
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D007271:Injections, Intradermal; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D008297:Male; D051379:Mice; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D053495:Osteopontin; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D012795:Sialoglycoproteins / Q000276:immunology / Q000494:pharmacology / Q000502:physiology*; D012867:Skin / Q000473:pathology
chemical_list: D000906:Antibodies; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; C506897:Spp1 protein, rat; D053495:Osteopontin; D009240:N-Formylmethionine Leucyl-Phenylalanine